ResMed (RMD)
(Delayed Data from NYSE)
$203.15 USD
-0.73 (-0.36%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $203.00 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
ResMed (RMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$214.22 | $238.00 | $180.00 | 5.45% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for ResMed comes to $214.22. The forecasts range from a low of $180.00 to a high of $238.00. The average price target represents an increase of 5.45% from the last closing price of $203.15.
Analyst Price Targets (9 )
Broker Rating
ResMed currently has an average brokerage recommendation (ABR) of 1.96 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.68 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, six are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 42.86% and 14.29% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RMD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 8 | 8 | 8 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 6 | 6 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.96 | 1.96 | 1.68 | 1.68 | 1.68 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/24/2024 | Not Identified | Not Identified | Strong Buy | Hold |
4/26/2024 | KeyBanc Capital Markets | Brett Fishbin | Strong Buy | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
3/27/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
1/29/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
1/26/2024 | UBS | Laura Sutcliffe | Hold | Hold |
9/30/2023 | Goldman Sachs | Chris Cooper | Not Available | Strong Buy |
9/29/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.96 |
ABR (Last week) | 1.96 |
# of Recs in ABR | 14 |
Average Target Price | $214.22 |
LT Growth Rate | 13.30% |
Industry | Medical - Products |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | 2.02 |